Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies

Round 1

Reviewer 1 Report

In this review article, Braun and Schrader have provided comprehensive information about immunotherapy modalities available to patients with mature T-cell malignancies. The review article overall is well-written and the authors have addressed different therapeutic approaches which target different components of the immune system. It would be great if the authors could include a figure/ time line of FDA approval of different drugs which target the immune system for these types of cancers.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

The manuscript is well written. The language is clear and professional. The authors focused on monoclonal as well as bispecific antibodies, immune-checkpoint blockades, and CAR T-cell therapies on mature T-cell leukemia / lymphoma (MTCL/L). The authors also pointed out further study directions in this field.

In general, the authors summarized the field well. However, it would be better if the author can mention more the differences between different MTCL/L subtypes and correlate different therapies with different subtypes.

 

 

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 3 Report

The authors present a review of immunology-based therapeutic options for mature T-cell malignancies. The topic is relevant as there have been poor therapeutic options for this disease group to date, but the new immunotherapies are likely to change things. Title, simple abstract and abstract are informative. In the introduction, the new WHO systematics result in a blur because with Figure 1, NK cell neoplasms now suddenly appear. This needs to be explained or modified at this point. In addition, it is important in Fig. 1 that it is only the representation in adults, this should not be hidden in the legend. In the 2nd chapter it is unusual that the presentation starts with ADC, this should be placed after antibodies. Chapter 2.2 surprisingly starts with rituximab. The complete paragraph seems dispensable, instead 2.2.1, the presentation of mechanisms, is a good introduction (new 2.2), before then presenting the different T-cell directed mAb. 

Chapter 3 Bispecific antibodies also reverts to B-cell directed therapies again without explanation, this rather confuses or should be clearly delineated as an analogy. The presentation of cellular therapies, discussion and conclusions are easy to read.  

Author Response

Please see the attachment

Author Response File: Author Response.pdf